How many Mosunetuzumab clinical trials are there?

54 Mosunetuzumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 31 are actively recruiting participants. 6 are marked completed.

Are Mosunetuzumab clinical trials recruiting in 2026?

Yes — 31 Mosunetuzumab trials are actively recruiting in 2026, with 444 U.S. sites across 45 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Mosunetuzumab being studied for?

Mosunetuzumab is being studied for Follicular Lymphoma, Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma and 91 more. The trials are grouped by indication on this page.

What phase is Mosunetuzumab in?

Mosunetuzumab clinical trials span 5 Phase 3, 28 Phase 2, 9 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Mosunetuzumab clinical trials?

The lead sponsor across the most Mosunetuzumab trials is Hoffmann-La Roche, with 30 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Mosunetuzumab Clinical Trials (2026): 54 Studies for Follicular Lymphoma & Non-Hodgkin Lymphoma

Creator: Hipa.ai Research
Published: 2026-05-27T18:54:26.044Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

54 Mosunetuzumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 39 indications (including Follicular Lymphoma & Non-Hodgkin Lymphoma) and 6,881 total planned enrollment. 5 Phase 3 Mosunetuzumab trials and 28 Phase 2 are listed. 36 Mosunetuzumab clinical trials are actively recruiting at 444 U.S. sites across 45 states. Most recent activity: NCT07548450 (Jun 2035).

Where to Participate: All Mosunetuzumab Trial Sites in the U.S. (444 sites across 45 states)

Every actively recruiting Mosunetuzumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	University of Alabama at Birmingham Cancer Center	Birmingham35233	NCT06337318	Map
AZ	Mayo Clinic Hospital in Arizona	Phoenix85054	NCT06337318	Map
AZ	Mayo Clinic in Arizona - Phoenix	Phoenix85054	NCT06090539	Map
AZ	Mayo Clinic Phoenix	Phoenix85054-4502	NCT06634589	Map
AZ	Banner University Medical Center - Tucson	Tucson85719	NCT05633615	Map
AZ	Banner University Medical Center - Tucson	Tucson85719	NCT06337318	Map
AZ	University of Arizona Cancer Center-North Campus	Tucson85719	NCT05633615	Map
AZ	University of Arizona Cancer Center-North Campus	Tucson85719	NCT06337318	Map
AR	Highlands Oncology Group - Fayetteville	Fayetteville72703	NCT05633615	Map
AR	Highlands Oncology Group - Fayetteville	Fayetteville72703	NCT06337318	Map
AR	University of Arkansas for Medical Sciences	Little Rock72205	NCT05633615	Map
AR	University of Arkansas for Medical Sciences	Little Rock72205	NCT06337318	Map
AR	Highlands Oncology Group - Rogers	Rogers72758	NCT05633615	Map
AR	Highlands Oncology Group - Rogers	Rogers72758	NCT06337318	Map
AR	Highlands Oncology Group	Springdale72762	NCT05633615	Map
AR	Highlands Oncology Group	Springdale72762	NCT06337318	Map
CA	Tower Cancer Research Foundation	Beverly Hills90211	NCT06337318	Map
CA	University of California San Francisco - Fresno Center for Medical Education and Research	Clovis93611	NCT04970901	Map
CA	UC Irvine Health Cancer Center-Newport	Costa Mesa92627	NCT05633615	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT05886036	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT06015880	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT06090539	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT06337318	Map
CA	City of Hope Medical Center	Duarte91010	NCT05672251	Map
CA	City of Hope Medical Center	Duarte91010	NCT06453044	Map
CA	City of Hope at Irvine Lennar	Irvine92618	NCT06337318	Map
CA	UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care	Irvine92612	NCT05633615	Map
CA	UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care	Irvine92612	NCT06337318	Map
CA	UCI Health Laguna Hills	Laguna Hills92653	NCT05633615	Map
CA	City of Hope Antelope Valley	Lancaster93534	NCT06337318	Map
CA	City of Hope at Long Beach Elm	Long Beach90813	NCT06337318	Map
CA	Tibor Rubin VA Medical Center	Long Beach90822	NCT06337318	Map
CA	Cedars-Sinai Medical Center	Los Angeles90048	NCT06337318	Map
CA	University of Southern California Norris Comprehensive	Los Angeles90033	NCT06634589	Map
CA	UC Irvine Health/Chao Family Comprehensive Cancer Center	Orange92868	NCT05633615	Map
CA	UC Irvine Health/Chao Family Comprehensive Cancer Center	Orange92868	NCT06337318	Map
CA	University of California Davis Comprehensive Cancer Center	Sacramento95817	NCT06015880	Map
CA	Scripps Health - Prebys Cancer Center	San Diego92103	NCT04970901	Map
CA	UCSF Medical Center-Parnassus	San Francisco94143	NCT05633615	Map
CA	UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program	San Francisco94143	NCT05169515	Map
CA	City of Hope South Pasadena	South Pasadena91030	NCT06337318	Map
CA	Torrance Memorial Physician Network - Cancer Care	Torrance90505	NCT06337318	Map
CA	City of Hope Upland	Upland91786	NCT06337318	Map
CO	UCHealth University of Colorado Hospital	Aurora80045	NCT06337318	Map
CO	University of Colorado	Aurora80045	NCT05169515	Map
CO	Cancer Care and Hematology-Fort Collins	Fort Collins80528	NCT06337318	Map
CO	Poudre Valley Hospital	Fort Collins80524	NCT06337318	Map
CO	UCHealth Greeley Hospital	Greeley80631	NCT06337318	Map
CO	Medical Center of the Rockies	Loveland80538	NCT06337318	Map
DE	Helen F Graham Cancer Center	Newark19713	NCT06337318	Map
DE	Medical Oncology Hematology Consultants PA	Newark19713	NCT06337318	Map
DC	Georgetown University (Data Collection Only)	Washington D.C.20007	NCT05389293	Map
DC	MedStar Georgetown University Hospital	Washington D.C.20007	NCT06337318	Map
DC	Sibley Memorial Hospital	Washington D.C.20016	NCT06337318	Map
FL	UM Sylvester Comprehensive Cancer Center at Aventura	Aventura33180	NCT05886036	Map
FL	UM Sylvester Comprehensive Cancer Center at Aventura	Aventura33180	NCT06337318	Map
FL	UM Sylvester Comprehensive Cancer Center at Coral Gables	Coral Gables33146	NCT05886036	Map
FL	UM Sylvester Comprehensive Cancer Center at Coral Gables	Coral Gables33146	NCT06337318	Map
FL	UM Sylvester Comprehensive Cancer Center at Coral Springs	Coral Springs33065	NCT05886036	Map
FL	UM Sylvester Comprehensive Cancer Center at Coral Springs	Coral Springs33065	NCT06337318	Map
FL	UM Sylvester Comprehensive Cancer Center at Deerfield Beach	Deerfield Beach33442	NCT05886036	Map
FL	UM Sylvester Comprehensive Cancer Center at Deerfield Beach	Deerfield Beach33442	NCT06337318	Map
FL	UM Sylvester Comprehensive Cancer Center at Doral	Doral33166	NCT05886036	Map
FL	UM Sylvester Comprehensive Cancer Center at Doral	Doral33166	NCT06337318	Map
FL	UF Health Cancer Institute - Gainesville	Gainesville32610	NCT05633615	Map
FL	UM Sylvester Comprehensive Cancer Center at Hollywood	Hollywood33021	NCT05886036	Map
FL	UM Sylvester Comprehensive Cancer Center at Hollywood	Hollywood33021	NCT06337318	Map
FL	Mayo Clinic in Florida	Jacksonville32224-9980	NCT06337318	Map
FL	Mayo Clinic Jacksonville	Jacksonville32224-1865	NCT06634589	Map
FL	Miami Cancer Institute	Miami33176	NCT04970901	Map
FL	Sylvester Comprehensive Cancer Center	Miami33136	NCT04970901	Map
FL	UM Sylvester Comprehensive Cancer Center at Kendall	Miami33176	NCT05886036	Map
FL	UM Sylvester Comprehensive Cancer Center at Kendall	Miami33176	NCT06337318	Map
FL	University of Miami	Miami33136	NCT05260957	Map
FL	University of Miami	Miami33136	NCT06569680	Map
FL	University of Miami Miller School of Medicine-Sylvester Cancer Center	Miami33136	NCT05886036	Map
FL	University of Miami Miller School of Medicine-Sylvester Cancer Center	Miami33136	NCT06337318	Map
FL	Mount Sinai Medical Center	Miami Beach33140	NCT06337318	Map
FL	University of Miami Sylvester Comprehensive Cancer Center at Sole Mia	North Miami33181	NCT06337318	Map
FL	Memorial Cancer Institute - Memorial Hospital West	Pembroke Pines33028	NCT04970901	Map
FL	Memorial Hospital West	Pembroke Pines33028	NCT06337318	Map
FL	UM Sylvester Comprehensive Cancer Center at Plantation	Plantation33324	NCT05886036	Map
FL	UM Sylvester Comprehensive Cancer Center at Plantation	Plantation33324	NCT06337318	Map
FL	Moffitt Cancer Center	Tampa33612	NCT05169515	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06090539	Map
FL	Moffitt Cancer Center	Tampa33612-9496	NCT06634589	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT05633615	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT06337318	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT06337318	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT05633615	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT05886036	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT06337318	Map
GA	The Blood and Marrow Transplant Group of Georgia	Atlanta30342	NCT04970901	Map
GA	Winship Cancer Institute of Emory University	Atlanta30322	NCT04970901	Map
GA	Augusta University Medical Center	Augusta30912	NCT06337318	Map
ID	Saint Alphonsus Cancer Care Center-Boise	Boise83706	NCT06337318	Map
ID	Saint Luke's Cancer Institute - Boise	Boise83712	NCT05633615	Map
ID	Saint Alphonsus Cancer Care Center-Caldwell	Caldwell83605	NCT06337318	Map
ID	Kootenai Health - Coeur d'Alene	Coeur d'Alene83814	NCT06337318	Map
ID	Saint Luke's Cancer Institute - Fruitland	Fruitland83619	NCT05633615	Map
ID	Saint Luke's Cancer Institute - Meridian	Meridian83642	NCT05633615	Map
ID	Saint Alphonsus Cancer Care Center-Nampa	Nampa83687	NCT06337318	Map
ID	Saint Luke's Cancer Institute - Nampa	Nampa83687	NCT05633615	Map
ID	Kootenai Clinic Cancer Services - Post Falls	Post Falls83854	NCT06337318	Map
ID	Kootenai Clinic Cancer Services - Sandpoint	Sandpoint83864	NCT06337318	Map
ID	Saint Luke's Cancer Institute - Twin Falls	Twin Falls83301	NCT05633615	Map
IL	Northwestern University	Chicago60611	NCT06015880	Map
IL	Swedish Covenant Hospital	Chicago60625	NCT06337318	Map
IL	The University of Chicago	Chicago60637	NCT05169515	Map
IL	University of Chicago Comprehensive Cancer Center	Chicago60637	NCT05633615	Map
IL	University of Chicago Comprehensive Cancer Center	Chicago60637	NCT06337318	Map
IL	University of Illinois	Chicago60612	NCT05633615	Map
IL	Carle at The Riverfront	Danville61832	NCT06337318	Map
IL	Cancer Care Specialists of Illinois - Decatur	Decatur62526	NCT06337318	Map
IL	Decatur Memorial Hospital	Decatur62526	NCT06337318	Map
IL	Carle Physician Group-Effingham	Effingham62401	NCT06337318	Map
IL	Crossroads Cancer Center	Effingham62401	NCT06337318	Map
IL	Elmhurst Memorial Hospital	Elmhurst60126	NCT06337318	Map
IL	NorthShore University HealthSystem-Evanston Hospital	Evanston60201	NCT06337318	Map
IL	NorthShore University HealthSystem-Glenbrook Hospital	Glenview60026	NCT06337318	Map
IL	NorthShore University HealthSystem-Highland Park Hospital	Highland Park60035	NCT06337318	Map
IL	Carle Physician Group-Mattoon/Charleston	Mattoon61938	NCT06337318	Map
IL	Edward Hospital/Cancer Center	Naperville60540	NCT06337318	Map
IL	UC Comprehensive Cancer Center at Silver Cross	New Lenox60451	NCT06337318	Map
IL	Cancer Care Center of O'Fallon	O'Fallon62269	NCT06337318	Map
IL	University of Chicago Medicine-Orland Park	Orland Park60462	NCT06337318	Map
IL	Edward Hospital/Cancer Center?Plainfield	Plainfield60585	NCT06337318	Map
IL	Memorial Hospital East	Shiloh62269	NCT06337318	Map
IL	Southern Illinois University School of Medicine	Springfield62702	NCT06337318	Map
IL	Springfield Clinic	Springfield62702	NCT06337318	Map
IL	Springfield Memorial Hospital	Springfield62781	NCT06337318	Map
IL	Carle Cancer Center	Urbana61801	NCT06337318	Map
IN	UChicago Medicine Northwest Indiana	Crown Point46307	NCT06337318	Map
IN	Northwest Cancer Center - Hobart	Hobart46342	NCT06337318	Map
IN	Indiana University/Melvin and Bren Simon Cancer Center	Indianapolis46202	NCT06337318	Map
IA	Mary Greeley Medical Center	Ames50010	NCT06337318	Map
IA	McFarland Clinic - Ames	Ames50010	NCT06337318	Map
IA	UI Health Care Mission Cancer and Blood - Ankeny Clinic	Ankeny50023	NCT06337318	Map
IA	University of Iowa Healthcare Cancer Services Quad Cities	Bettendorf52722	NCT06337318	Map
IA	Mercy Hospital	Cedar Rapids52403	NCT06337318	Map
IA	Oncology Associates at Mercy Medical Center	Cedar Rapids52403	NCT06337318	Map
IA	UI Health Care Mission Cancer and Blood - West Des Moines Clinic	Clive50325	NCT06337318	Map
IA	Iowa Methodist Medical Center	Des Moines50309	NCT06337318	Map
IA	Mission Cancer + Blood - Mission Cancer Foundation	Des Moines50309	NCT04970901	Map
IA	UI Health Care Mission Cancer and Blood - Des Moines Clinic	Des Moines50309	NCT06337318	Map
IA	UI Health Care Mission Cancer and Blood - Laurel Clinic	Des Moines50314	NCT06337318	Map
IA	McFarland Clinic - Trinity Cancer Center	Fort Dodge50501	NCT06337318	Map
IA	University of Iowa/Holden Comprehensive Cancer Center	Iowa City52242	NCT05633615	Map
IA	University of Iowa/Holden Comprehensive Cancer Center	Iowa City52242	NCT06337318	Map
IA	McFarland Clinic - Marshalltown	Marshalltown50158	NCT06337318	Map
IA	UI Health Care Mission Cancer and Blood - Waukee Clinic	Waukee50263	NCT06337318	Map
KS	HaysMed	Hays67601	NCT06337318	Map
KS	University of Kansas Cancer Center	Kansas City66160	NCT05633615	Map
KS	University of Kansas Cancer Center	Kansas City66160	NCT05886036	Map
KS	University of Kansas Cancer Center	Kansas City66160	NCT06337318	Map
KS	Lawrence Memorial Hospital	Lawrence66044	NCT06337318	Map
KS	The University of Kansas Cancer Center - Olathe	Olathe66061	NCT06337318	Map
KS	University of Kansas Cancer Center-Overland Park	Overland Park66210	NCT05633615	Map
KS	University of Kansas Cancer Center-Overland Park	Overland Park66210	NCT05886036	Map
KS	University of Kansas Cancer Center-Overland Park	Overland Park66210	NCT06337318	Map
KS	Salina Regional Health Center	Salina67401	NCT06337318	Map
KS	University of Kansas Health System Saint Francis Campus	Topeka66606	NCT06337318	Map
KS	The University of Kansas Cancer Center	Westwood66205-2003	NCT06634589	Map
KS	University of Kansas Hospital-Westwood Cancer Center	Westwood66205	NCT05633615	Map
KS	University of Kansas Hospital-Westwood Cancer Center	Westwood66205	NCT05886036	Map
KS	University of Kansas Hospital-Westwood Cancer Center	Westwood66205	NCT06337318	Map
KY	The James Graham Brown Cancer Center at University of Louisville	Louisville40202	NCT05633615	Map
KY	UofL Health Medical Center Northeast	Louisville40245	NCT05633615	Map
LA	LSU Health Baton Rouge-North Clinic	Baton Rouge70805	NCT06337318	Map
LA	Our Lady of the Lake Physician Group	Baton Rouge70808	NCT06337318	Map
MD	Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore21287	NCT05633615	Map
MD	Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore21287	NCT06337318	Map
MD	University of Maryland/Greenebaum Cancer Center	Baltimore21201	NCT05633615	Map
MD	Walter Reed National Military Medical Center	Bethesda20889-5600	NCT06337318	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT04970901	Map
MA	Brigham & Women's Hospital	Boston02215	NCT07052695	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT04970901	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT06090539	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT07052695	Map
MI	University of Michigan Rogel Cancer Center	Ann Arbor48109	NCT06337318	Map
MI	Bronson Battle Creek	Battle Creek49017	NCT05633615	Map
MI	Bronson Battle Creek	Battle Creek49017	NCT06337318	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Brighton	Brighton48114	NCT06337318	Map
MI	Henry Ford Cancer Institute-Downriver	Brownstown48183	NCT06337318	—
MI	Trinity Health IHA Medical Group Hematology Oncology - Canton	Canton48188	NCT06337318	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital	Chelsea48118	NCT06337318	Map
MI	Henry Ford Macomb Hospital-Clinton Township	Clinton Township48038	NCT06337318	Map
MI	Henry Ford Medical Center-Fairlane	Dearborn48126	NCT06337318	Map
MI	Henry Ford Hospital	Detroit48202	NCT05633615	Map
MI	Henry Ford Hospital	Detroit48202	NCT06337318	Map
MI	Wayne State University/Karmanos Cancer Institute	Detroit48201	NCT05633615	Map
MI	Wayne State University/Karmanos Cancer Institute	Detroit48201	NCT06337318	Map
MI	Weisberg Cancer Treatment Center	Farmington Hills48334	NCT05633615	Map
MI	Weisberg Cancer Treatment Center	Farmington Hills48334	NCT06337318	Map
MI	Cancer Hematology Centers - Flint	Flint48503	NCT06337318	Map
MI	Genesys Hurley Cancer Institute	Flint48503	NCT06337318	Map
MI	Corewell Health Grand Rapids Hospitals - Butterworth Hospital	Grand Rapids49503	NCT05633615	Map
MI	Corewell Health Grand Rapids Hospitals - Butterworth Hospital	Grand Rapids49503	NCT06337318	Map
MI	Trinity Health Grand Rapids Hospital	Grand Rapids49503	NCT05633615	Map
MI	Trinity Health Grand Rapids Hospital	Grand Rapids49503	NCT06337318	Map
MI	Allegiance Health	Jackson49201	NCT06337318	Map
MI	Beacon Kalamazoo Cancer Center	Kalamazoo49009	NCT05633615	Map
MI	Bronson Methodist Hospital	Kalamazoo49007	NCT05633615	Map
MI	Bronson Methodist Hospital	Kalamazoo49007	NCT06337318	Map
MI	West Michigan Cancer Center	Kalamazoo49007	NCT05633615	Map
MI	West Michigan Cancer Center	Kalamazoo49007	NCT06337318	Map
MI	University of Michigan Health - Sparrow Lansing	Lansing48912	NCT06337318	Map
MI	Trinity Health Saint Mary Mercy Livonia Hospital	Livonia48154	NCT06337318	Map
MI	Trinity Health Muskegon Hospital	Muskegon49444	NCT05633615	Map
MI	Trinity Health Muskegon Hospital	Muskegon49444	NCT06337318	Map
MI	Corewell Health Lakeland Hospitals - Niles Hospital	Niles49120	NCT05633615	Map
MI	Corewell Health Lakeland Hospitals - Niles Hospital	Niles49120	NCT06337318	Map
MI	Cancer and Hematology Centers of Western Michigan - Norton Shores	Norton Shores49444	NCT05633615	Map
MI	Cancer and Hematology Centers of Western Michigan - Norton Shores	Norton Shores49444	NCT06337318	Map
MI	Henry Ford Health Providence Novi Hospital	Novi48374	NCT06337318	Map
MI	Henry Ford Medical Center-Columbus	Novi48377	NCT06337318	Map
MI	Hope Cancer Center	Pontiac48341	NCT06337318	Map
MI	Trinity Health Saint Joseph Mercy Oakland Hospital	Pontiac48341	NCT06337318	Map
MI	Corewell Health Reed City Hospital	Reed City49677	NCT05633615	Map
MI	Corewell Health Reed City Hospital	Reed City49677	NCT06337318	Map
MI	Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center	Saint Joseph49085	NCT05633615	Map
MI	Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center	Saint Joseph49085	NCT06337318	Map
MI	Corewell Health Lakeland Hospitals - Saint Joseph Hospital	Saint Joseph49085	NCT06337318	Map
MI	Henry Ford Health Providence Southfield Hospital	Southfield48075	NCT06337318	Map
MI	Munson Medical Center	Traverse City49684	NCT05633615	Map
MI	Munson Medical Center	Traverse City49684	NCT06337318	Map
MI	Henry Ford West Bloomfield Hospital	West Bloomfield48322	NCT06337318	Map
MI	Henry Ford Wyandotte Hospital	Wyandotte48192	NCT06337318	Map
MI	University of Michigan Health - West	Wyoming49519	NCT05633615	Map
MI	University of Michigan Health - West	Wyoming49519	NCT06337318	Map
MI	Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus	Ypsilanti48197	NCT06337318	Map
MN	Essentia Health Saint Joseph's Medical Center	Brainerd56401	NCT06337318	Map
MN	Minnesota Oncology - Burnsville	Burnsville55337	NCT06337318	Map
MN	Mercy Hospital	Coon Rapids55433	NCT06337318	Map
MN	Essentia Health - Deer River Clinic	Deer River56636	NCT06337318	Map
MN	Essentia Health Cancer Center	Duluth55805	NCT06337318	Map
MN	Fairview Southdale Hospital	Edina55435	NCT06337318	Map
MN	Essentia Health Hibbing Clinic	Hibbing55746	NCT06337318	Map
MN	Abbott-Northwestern Hospital	Minneapolis55407	NCT06337318	Map
MN	University of Minnesota	Minneapolis55455	NCT04970901	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT06337318	Map
MN	Mayo Clinic in Rochester, Minnesota	Rochester55905	NCT06090539	Map
MN	Mayo Clinic Rochester	Rochester55902	NCT05091424	Map
MN	Mayo Clinic Rochester	Rochester55905-0001	NCT06634589	Map
MN	Park Nicollet Clinic - Saint Louis Park	Saint Louis Park55416	NCT06337318	Map
MN	Regions Hospital	Saint Paul55101	NCT06337318	Map
MN	United Hospital	Saint Paul55102	NCT06337318	Map
MN	Essentia Health Sandstone	Sandstone55072	NCT06337318	Map
MN	Saint Francis Regional Medical Center	Shakopee55379	NCT06337318	Map
MN	Essentia Health Virginia Clinic	Virginia55792	NCT06337318	Map
MS	Baptist Memorial Hospital and Cancer Center-Desoto	Southhaven38671	NCT06337318	Map
MO	Saint Francis Medical Center	Cape Girardeau63703	NCT06337318	Map
MO	Saint Luke's Hospital	Chesterfield63017	NCT06337318	Map
MO	Siteman Cancer Center at Saint Peters Hospital	City of Saint Peters63376	NCT06337318	Map
MO	Siteman Cancer Center at West County Hospital	Creve Coeur63141	NCT06337318	Map
MO	Parkland Health Center - Farmington	Farmington63640	NCT06337318	Map
MO	Kansas City Veterans Affairs Medical Center	Kansas City64128	NCT06337318	Map
MO	University Health Truman Medical Center	Kansas City64108	NCT06337318	Map
MO	University of Kansas Cancer Center - Briarcliff	Kansas City64116	NCT05886036	Map
MO	University of Kansas Cancer Center - Briarcliff	Kansas City64116	NCT06337318	Map
MO	University of Kansas Cancer Center - North	Kansas City64154	NCT05886036	Map
MO	University of Kansas Cancer Center - North	Kansas City64154	NCT06337318	Map
MO	University of Kansas Cancer Center - Lee's Summit	Lee's Summit64064	NCT05886036	Map
MO	University of Kansas Cancer Center - Lee's Summit	Lee's Summit64064	NCT06337318	Map
MO	Sainte Genevieve County Memorial Hospital	Sainte Genevieve63670	NCT06337318	Map
MO	Missouri Baptist Medical Center	St Louis63131	NCT06337318	Map
MO	Siteman Cancer Center at Christian Hospital	St Louis63136	NCT06337318	Map
MO	Siteman Cancer Center-South County	St Louis63129	NCT06337318	Map
MO	Washington University School of Medicine	St Louis63110	NCT06337318	Map
MO	Washington University School of Medicine	St Louis63110-1010	NCT06634589	Map
MO	Missouri Baptist Sullivan Hospital	Sullivan63080	NCT06337318	Map
MO	BJC Outpatient Center at Sunset Hills	Sunset Hills63127	NCT06337318	Map
MT	Community Hospital of Anaconda	Anaconda59711	NCT06337318	Map
MT	Billings Clinic Cancer Center	Billings59101	NCT06337318	Map
MT	Bozeman Health Deaconess Hospital	Bozeman59715	NCT06337318	Map
MT	Benefis Sletten Cancer Institute	Great Falls59405	NCT06337318	Map
MT	Logan Health Medical Center	Kalispell59901	NCT06337318	Map
MT	Community Medical Center	Missoula59804	NCT06337318	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT04889716	Map
NV	OptumCare Cancer Care at Charleston	Las Vegas89102	NCT06337318	Map
NV	OptumCare Cancer Care at Fort Apache	Las Vegas89183	NCT06337318	Map
NH	Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center	Lebanon03756	NCT05633615	Map
NH	Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center	Lebanon03756	NCT06337318	Map
NJ	Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities	Basking Ridge07920	NCT05389293	Map
NJ	Memorial Sloan Kettering Basking Ridge	Basking Ridge07920	NCT05886036	Map
NJ	Summit Medical Group	Florham Park07932-1049	NCT06634589	Map
NJ	Hackensack Meridian Health (Data collection only)	Hackensack07601	NCT05389293	Map
NJ	Saint Barnabas Medical Center	Livingston07039	NCT06337318	Map
NJ	Monmouth Medical Center	Long Branch07740	NCT06337318	Map
NJ	Memorial Sloan Kettering Monmouth	Middletown07748	NCT05886036	Map
NJ	Memorial Sloan Kettering Monmouth (Limited protocol activities)	Middletown07748	NCT05389293	Map
NJ	Memorial Sloan Kettering Bergen	Montvale07645	NCT05886036	Map
NJ	Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale07645	NCT05389293	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08901	NCT04792502	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT06337318	Map
NM	University of New Mexico Cancer Center	Albuquerque87106	NCT05633615	Map
NY	Memorial Sloan Kettering Commack	Commack11725	NCT05886036	Map
NY	Memorial Sloan Kettering Suffolk- Commack (Limited protocol activities)	Commack11725	NCT05389293	Map
NY	Memorial Sloan Kettering Westchester	Harrison10604	NCT05886036	Map
NY	Memorial Sloan Kettering Westchester (Limited protocol activities)	Harrison10604	NCT05389293	Map
NY	Columbia University Irving Medical Center	New York10027	NCT04970901	Map
NY	Columbia University Medical Center	New York10032	NCT06634589	Map
NY	Icahn School of Medicine At Mount Sinai	New York10029-6504	NCT06634589	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT05389293	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT05886036	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06090539	Map
NY	Memorial Sloan Kettering Cancer Center Mskcc	New York10065-6800	NCT06634589	Map
NY	NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center	New York10032	NCT05633615	Map
NY	Weill Cornell Medical College Newyork Presbyterian Hospital	New York10065-4870	NCT06634589	Map
NY	University of Rochester	Rochester14642	NCT05633615	Map
NY	University of Rochester	Rochester14642	NCT06337318	Map
NY	University of Rochester	Rochester14642-0001	NCT06634589	Map
NY	Wilmot Cancer Institute	Rochester14642	NCT06828991	Map
NY	Memorial Sloan Kettering Nassau (Limited protocol activities)	Rockville Centre11553	NCT05389293	Map
NY	Memorial Sloan Kettering Nassau	Uniondale11553	NCT05886036	Map
NY	Wilmot Cancer Institute at Webster	Webster14580	NCT05633615	Map
NY	Wilmot Cancer Institute at Webster	Webster14580	NCT06337318	Map
NC	UNC Lineberger Comprehensive Cancer Center	Chapel Hill27599	NCT06337318	Map
NC	Atrium Health Pineville/LCI-Pineville	Charlotte28210	NCT06337318	Map
NC	Atrium Health University City/LCI-University	Charlotte28262	NCT06337318	Map
NC	Carolinas Medical Center/Levine Cancer Institute	Charlotte28203	NCT05633615	Map
NC	Carolinas Medical Center/Levine Cancer Institute	Charlotte28203	NCT06337318	Map
NC	Levine Cancer Institute	Charlotte28204	NCT05169515	Map
NC	Levine Cancer Institute-SouthPark	Charlotte28211	NCT06337318	Map
NC	Novant Health Presbyterian Medical Center	Charlotte28204	NCT06337318	Map
NC	Wake Forest University at Clemmons	Clemmons27012	NCT06337318	Map
NC	Southeastern Medical Oncology Center-Clinton	Clinton28328	NCT06337318	Map
NC	Atrium Health Cabarrus/LCI-Concord	Concord28025	NCT05633615	Map
NC	Atrium Health Cabarrus/LCI-Concord	Concord28025	NCT06337318	Map
NC	Duke University Medical Center	Durham27710	NCT06337318	Map
NC	Southeastern Medical Oncology Center-Goldsboro	Goldsboro27534	NCT06337318	Map
NC	Southeastern Medical Oncology Center-Jacksonville	Jacksonville28546	NCT06337318	Map
NC	Atrium Health Union/LCI-Union	Monroe28112	NCT06337318	Map
NC	Novant Health Cancer Institute - Mooresville	Mooresville28117	NCT06337318	Map
NC	Novant Health Forsyth Medical Center	Winston-Salem27103	NCT06337318	Map
NC	Wake Forest University Health Sciences	Winston-Salem27157	NCT05633615	Map
NC	Wake Forest University Health Sciences	Winston-Salem27157	NCT05886036	Map
NC	Wake Forest University Health Sciences	Winston-Salem27157	NCT06015880	Map
NC	Wake Forest University Health Sciences	Winston-Salem27157	NCT06337318	Map
ND	Essentia Health Cancer Center-South University Clinic	Fargo58103	NCT06337318	Map
ND	Sanford Broadway Medical Center	Fargo58122	NCT05633615	Map
ND	Sanford Roger Maris Cancer Center	Fargo58122	NCT05633615	Map
OH	University of Cincinnati Cancer Center-UC Medical Center	Cincinnati45219	NCT05886036	Map
OH	Case Western Reserve University	Cleveland44106	NCT05633615	Map
OH	Case Western Reserve University	Cleveland44106	NCT06015880	Map
OH	Cleveland Clinic Main Campus	Cleveland44195	NCT04970901	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT05886036	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT06337318	Map
OH	The James Cancer Hospital and Solove Research Institute	Columbus43210	NCT05091424	Map
OH	University of Cincinnati Cancer Center-West Chester	West Chester45069	NCT05886036	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT05633615	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT05886036	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT06015880	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT06337318	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT05633615	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT06337318	Map
OR	Saint Alphonsus Cancer Care Center-Ontario	Ontario97914	NCT06337318	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT05633615	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT06337318	Map
OR	Kaiser Permanente Northwest	Portland97227	NCT06337318	Map
OR	OHSU Knight Cancer Institute	Portland97239	NCT06249191	Map
OR	Oregon Health and Science University	Portland97239	NCT04970901	Map
OR	Oregon Health and Science University	Portland97239	NCT05633615	Map
OR	Oregon Health and Science University	Portland97239	NCT06337318	Map
OR	Providence Portland Medical Center	Portland97213	NCT05633615	Map
OR	Providence Portland Medical Center	Portland97213	NCT06337318	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT05633615	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT06337318	Map
PA	Geisinger Medical Center	Danville17822	NCT05633615	Map
PA	Abramson Cancer Center of the University of Pennsylvania	Philadelphia19104	NCT04889716	Map
PA	Fox Chase Cancer Center	Philadelphia19111	NCT06337318	Map
PA	Fox Chase Cancer Center	Philadelphia19111-2434	NCT06634589	Map
PA	Penn Medicine - Perelman Center for Advanced Medicine	Philadelphia19104	NCT04970901	Map
PA	Thomas Jefferson University Hospital	Philadelphia19107	NCT06337318	Map
PA	University of Pennsylvania/Abramson Cancer Center	Philadelphia19104	NCT05633615	Map
PA	Geisinger Wyoming Valley/Henry Cancer Center	Wilkes-Barre18711	NCT05633615	Map
PA	Asplundh Cancer Pavilion	Willow Grove19090	NCT06337318	Map
RI	Brown University Health - Rhode Island Hospital	Providence02903	NCT04970901	Map
RI	Lifespan Cancer Insitute	Providence02903	NCT04792502	Map
RI	Rhode Island Hospital	Providence02903	NCT06337318	Map
SC	Prisma Health Cancer Institute - Spartanburg	Boiling Springs29316	NCT05633615	Map
SC	Medical University of South Carolina	Charleston29425	NCT05633615	Map
SC	Medical University of South Carolina	Charleston29425	NCT06337318	Map
SC	Prisma Health Cancer Institute - Easley	Easley29640	NCT05633615	Map
SC	Prisma Health Cancer Institute - Butternut	Greenville29605	NCT05633615	Map
SC	Prisma Health Cancer Institute - Eastside	Greenville29615	NCT05633615	Map
SC	Prisma Health Cancer Institute - Faris	Greenville29605	NCT05633615	Map
SC	Prisma Health Cancer Institute - Greer	Greer29650	NCT05633615	Map
SC	Prisma Health Cancer Institute - Seneca	Seneca29672	NCT05633615	Map
TN	Baptist Memorial Hospital and Cancer Center-Memphis	Memphis38120	NCT05633615	Map
TN	Baptist Memorial Hospital and Cancer Center-Memphis	Memphis38120	NCT06337318	Map
TN	Greco-Hainsworth Tennessee Oncology Centers for Research (GHCR)	Nashville37203	NCT04970901	Map
TX	Baylor University Medical Center	Dallas75246	NCT04970901	Map
TX	M D Anderson Cancer Center	Houston77030	NCT05615636	Map
TX	M D Anderson Cancer Center	Houston77030	NCT05886036	Map
TX	M D Anderson Cancer Center	Houston77030	NCT06337318	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06563505	Map
TX	The University of Texas Md Anderson Cancer Center	Houston77030-4009	NCT06634589	Map
TX	UT MD Anderson Cancer Center	Houston77030	NCT05169515	Map
TX	University of Texas Health Science Center at San Antonio	San Antonio78229	NCT06337318	Map
UT	Huntsman Cancer Institute	Salt Lake City84112	NCT04970901	Map
UT	Huntsman Cancer Institute	Salt Lake City84112-5550	NCT06634589	Map
UT	Huntsman Cancer Institute at The University of Utah	Salt Lake City84112	NCT05091424	Map
UT	Huntsman Cancer Institute/University of Utah	Salt Lake City84112	NCT05886036	Map
UT	Huntsman Cancer Institute/University of Utah	Salt Lake City84112	NCT06337318	Map
VT	University of Vermont and State Agricultural College	Burlington05405	NCT05633615	Map
VT	University of Vermont Medical Center	Burlington05401	NCT05633615	Map
VT	Dartmouth Cancer Center - North	Saint Johnsbury05819	NCT05633615	Map
VA	Emily Couric Clinical Cancer Center	Charlottesville22903	NCT04970901	Map
VA	University of Virginia Cancer Center	Charlottesville22908	NCT05886036	Map
VA	University of Virginia Cancer Center	Charlottesville22908	NCT06015880	Map
VA	University of Virginia Cancer Center	Charlottesville22908	NCT06337318	Map
VA	VCU Massey Cancer Center at Stony Point	Richmond23235	NCT06337318	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT05633615	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT05886036	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT06337318	Map
WA	Fred Hutch/University of Washington Cancer Consortium	Seattle98109	NCT06442475	Map
WA	Fred Hutch/University of Washington Cancer Consortium	Seattle98109	NCT06948786	Map
WA	Swedish Medical Center-First Hill	Seattle98122	NCT05633615	Map
WV	West Virginia University Charleston Division	Charleston25304	NCT06337318	Map
WI	ThedaCare Regional Cancer Center	Appleton54911	NCT06337318	Map
WI	ThedaCare Regional Medical Center - Appleton	Appleton54911	NCT06337318	Map
WI	Duluth Clinic Ashland	Ashland54806	NCT06337318	Map
WI	Marshfield Medical Center-EC Cancer Center	Eau Claire54701	NCT06337318	Map
WI	Gundersen Lutheran Medical Center	La Crosse54601	NCT06337318	Map
WI	University of Wisconsin	Madison53792-0001	NCT06634589	Map
WI	University of Wisconsin Carbone Cancer Center - Eastpark Medical Center	Madison53718	NCT05633615	Map
WI	University of Wisconsin Carbone Cancer Center - University Hospital	Madison53792	NCT05633615	Map
WI	Marshfield Medical Center-Marshfield	Marshfield54449	NCT06337318	Map
WI	Froedtert Menomonee Falls Hospital	Menomonee Falls53051	NCT06337318	Map
WI	Froedtert & Medical College of Wisconsin	Milwaukee53226	NCT04970901	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT05633615	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT06337318	Map
WI	Medical College of Wisconsin	Milwaukee53226-1222	NCT06634589	Map
WI	ProHealth D N Greenwald Center	Mukwonago53149	NCT06337318	Map
WI	Froedtert and MCW Moorland Reserve Health Center	New Berlin53151	NCT05633615	Map
WI	Froedtert and MCW Moorland Reserve Health Center	New Berlin53151	NCT06337318	Map
WI	Drexel Town Square Health Center	Oak Creek53154	NCT06337318	Map
WI	ProHealth Oconomowoc Memorial Hospital	Oconomowoc53066	NCT06337318	Map
WI	Marshfield Medical Center-River Region at Stevens Point	Stevens Point54482	NCT06337318	Map
WI	ProHealth Waukesha Memorial Hospital	Waukesha53188	NCT06337318	Map
WI	UW Cancer Center at ProHealth Care	Waukesha53188	NCT06337318	Map
WI	Froedtert West Bend Hospital/Kraemer Cancer Center	West Bend53095	NCT06337318	Map
WI	Marshfield Medical Center - Weston	Weston54476	NCT06337318	Map

Mosunetuzumab clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	completed	terminated	withdrawn	not yet recruiting	Total
P1	4	2	2		1		9
P1/P2	4	2	3	1	1		11
P2	19	3	1			5	28
P3	3	2					5
N/A	1						1

Recruiting Mosunetuzumab clinical trials (36)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT07548450	MPOWERMosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)	P2	Waldenstrom Macroglobulinemia	25	Jun 2026
NCT06284122	MorningLyteStudy of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5	P3	Follicular Lymphoma	790	Jun 2024
NCT06492837	FIL_MOZARTStudy With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients	P2	Follicular Lymphoma	56	Oct 2024
NCT07052695	Mosunetuzumab for CLL MRD Clearance	P1/P2	Leukemia	40	Nov 2025
NCT06006117	Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma	P3	Marginal Zone Lymphoma	260	Sep 2023
NCT06337318	Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma	P3	Classic Follicular Lymphoma	600	Oct 2024
NCT05091424	A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia	P1	Chronic Lymphocytic Leukemia	137	Mar 2022
NCT06948786	Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial	P2	Grade 1 Follicular Lymphoma	22	Nov 2025
NCT06569680	Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma	P2	Extranodal Marginal Zone Lymphoma	35	Nov 2024
NCT07566364	Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD	P2	Lymphocytic Leukemia	30	Oct 2026
NCT05633615	Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	P2	Diffuse Large B-Cell Lymphoma	396	Jun 2023
NCT06828991	GOLDA Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP	P2	Diffuse Large B-Cell Lymphoma (DLBCL)	40	Sep 2025
NCT06594939	Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma	P2	Diffuse Large B Cell Lymphoma (DLBCL)	31	Jun 2026
NCT07555470	CUREFL03Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma	P2	Follicular Lymphoma	80	Apr 2026
NCT06634589	A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies	P1/P2	B-cell Malignancy	80	Nov 2024
NCT05169515	A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma	P1	Non-Hodgkin Lymphoma	121	Oct 2022
NCT07191249	SCA Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).	P2	Follicular Lymphoma	30	Oct 2025
NCT06563505	A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma	P2	Lymphoma	36	Dec 2024
NCT05260957	NHLCAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).	P2	Refractory Non-Hodgkin Lymphoma	22	Dec 2022
NCT04889716	CAR-T Followed by Bispecific Antibodies	P2	Large B-cell Lymphoma	23	Nov 2021
NCT06090539	A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas	P1/P2	Relapsed/Refractory Non-Hodgkin Lymphoma	308	Dec 2023
NCT07598396	SOLUNAA Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis	P2	Lupus	30	May 2026
NCT05849857	MERLINMosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries	P2	Lymphoma, Follicular	80	Sep 2023
NCT06926205	GELLC9RICHTERCHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL	P2	Richter Syndrome	34	May 2024
NCT06453044	Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma	P2	Recurrent Grade 1 Follicular Lymphoma	41	Sep 2024
NCT04970901	LOTIS-7A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)	P1	B-Cell Non-Hodgkin Lymphoma	200	Jun 2022
NCT04792502	Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma	P2	Follicular Lymphoma	52	Jul 2022
NCT05615636	A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL	P2	Hodgkin Lymphoma	36	Apr 2023
NCT07031700	A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL	P2	Relapsed/Refractory Follicular Lymphoma	22	Jul 2025
NCT06015880	Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	P1	Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	30	May 2024
NCT06249191	Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma	P1/P2	Diffuse Large B-Cell Lymphoma	30	Jun 2024
NCT05672251	Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma	P2	Recurrent Diffuse Large B-Cell Lymphoma	36	Jan 2024
NCT06442475	Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma	P2	Ann Arbor Stage II Follicular Lymphoma	20	Aug 2024
NCT07278921	MosuOSSHSRStudy to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).	—	Relapsed/Refractory Follicular Lymphoma	25	Dec 2025
NCT05389293	A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma	P2	Follicular Lymphoma	152	May 2022
NCT05886036	Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial	P2	Nodular Lymphocyte Predominant B-Cell Lymphoma	70	Jan 2024

Mosunetuzumab clinical trials by indication

Follicular Lymphoma (8)

NCT	Acronym	Phase	Status	Title
NCT06284122	MorningLyte	P3	recruiting	Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
NCT05994235	—	P2	active not recruiting	Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
NCT06492837	FIL_MOZART	P2	recruiting	Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients
NCT04246086	—	P1/P2	active not recruiting	A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
NCT07555470	CUREFL03	P2	recruiting	Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
NCT07191249	SC	P2	not yet recruiting	A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).
NCT04792502	—	P2	recruiting	Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
NCT05389293	—	P2	recruiting	A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

Non-Hodgkin Lymphoma (4)

NCT	Acronym	Phase	Status	Title
NCT05169515	—	P1	recruiting	A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05207670	MorningSun	P2	active not recruiting	A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
NCT05171647	SUNMO	P3	active not recruiting	A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT05169658	—	P2	completed	Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Relapsed/Refractory Follicular Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT07031700	—	P2	not yet recruiting	A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL
NCT07278921	MosuOSSHSR	N/A	recruiting	Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).

Diffuse Large B-Cell Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT05633615	—	P2	recruiting	Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT06249191	—	P1/P2	recruiting	Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

Lymphoma, Follicular (2)

NCT	Acronym	Phase	Status	Title
NCT05410418	—	P2	active not recruiting	Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
NCT05849857	MERLIN	P2	recruiting	Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries

Large B-cell Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT05464329	—	P1	active not recruiting	Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
NCT04889716	—	P2	recruiting	CAR-T Followed by Bispecific Antibodies

B-cell Non-Hodgkin Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT03671018	BTCT4465A	P1/P2	active not recruiting	A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
NCT03677141	BTCT4465A	P1/P2	completed	A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Lymphocytic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT07566364	—	P2	not yet recruiting	Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD

Diffuse Large B Cell Lymphoma (DLBCL) (1)

NCT	Acronym	Phase	Status	Title
NCT06594939	—	P2	not yet recruiting	Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Waldenstrom Macroglobulinemia (1)

NCT	Acronym	Phase	Status	Title
NCT07548450	MPOWER	P2	not yet recruiting	Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)

Lupus (1)

NCT	Acronym	Phase	Status	Title
NCT07598396	SOLUNA	P2	recruiting	A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT07052695	—	P1/P2	recruiting	Mosunetuzumab for CLL MRD Clearance

Grade 1 Follicular Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT06948786	—	P2	recruiting	Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

Diffuse Large B-Cell Lymphoma (DLBCL) (1)

NCT	Acronym	Phase	Status	Title
NCT06828991	GOLD	P2	recruiting	A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT06563505	—	P2	recruiting	A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

B-cell Malignancy (1)

NCT	Acronym	Phase	Status	Title
NCT06634589	—	P1/P2	recruiting	A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Extranodal Marginal Zone Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT06569680	—	P2	recruiting	Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma

Classic Follicular Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT06337318	—	P3	recruiting	Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Recurrent Grade 1 Follicular Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT06453044	—	P2	recruiting	Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Ann Arbor Stage II Follicular Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT06442475	—	P2	recruiting	Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (1)

NCT	Acronym	Phase	Status	Title
NCT06015880	—	P1	recruiting	Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Richter Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT06926205	GELLC9RICHTER	P2	recruiting	CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL

Nodular Lymphocyte Predominant B-Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05886036	—	P2	recruiting	Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

Recurrent Diffuse Large B-Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05672251	—	P2	recruiting	Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Relapsed/Refractory Non-Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT06090539	—	P1/P2	recruiting	A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Marginal Zone Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT06006117	—	P3	recruiting	Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Refractory B-cell Acute Lymphoblastic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT05961696	—	P1	withdrawn	A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05615636	—	P2	recruiting	A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

B Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05412290	—	P1	active not recruiting	Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

Refractory Non-Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05260957	NHL	P2	recruiting	CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

B-Cell Non-Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT04970901	LOTIS-7	P1	recruiting	A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Non-Hodgkin Lymphoma, Follicular Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05315713	—	P1/P2	terminated	An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT05091424	—	P1	recruiting	A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Systemic Lupus Erythematosus (1)

NCT	Acronym	Phase	Status	Title
NCT05155345	—	P1	completed	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus

Relapsed Hematologic Malignancy (1)

NCT	Acronym	Phase	Status	Title
NCT05205252	ARIA	P1/P2	withdrawn	A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

Relapsed or Refractory Follicular Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT04712097	Celestimo	P3	active not recruiting	A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

B-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT04313608	—	P1	completed	A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03677154	BTCT4465A	P1/P2	completed	Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Lymphocytic Leukemia, Chronic (1)

NCT	Acronym	Phase	Status	Title
NCT02500407	NHL	P1/P2	completed	A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Mosunetuzumab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
MorningLyte	NCT06284122	P3	recruiting	Follicular Lymphoma	790	—
Celestimo	NCT04712097	P3	active not recruiting	Relapsed or Refractory Follicular Lymphoma	478	—
SUNMO	NCT05171647	P3	active not recruiting	Non-Hodgkin Lymphoma	208	PMID 41037766
MPOWER	NCT07548450	P2	not yet recruiting	Waldenstrom Macroglobulinemia	25	—
FIL_MOZART	NCT06492837	P2	recruiting	Follicular Lymphoma	56	—
GOLD	NCT06828991	P2	recruiting	Diffuse Large B-Cell Lymphoma (DLBCL)	40	—
CUREFL03	NCT07555470	P2	recruiting	Follicular Lymphoma	80	—
SC	NCT07191249	P2	not yet recruiting	Follicular Lymphoma	30	—
NHL	NCT05260957	P2	recruiting	Refractory Non-Hodgkin Lymphoma	22	—
SOLUNA	NCT07598396	P2	recruiting	Lupus	30	—
MERLIN	NCT05849857	P2	recruiting	Lymphoma, Follicular	80	—
GELLC9RICHTER	NCT06926205	P2	recruiting	Richter Syndrome	34	—
MorningSun	NCT05207670	P2	active not recruiting	Non-Hodgkin Lymphoma	320	—

Terminated and withdrawn Mosunetuzumab trials (3)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT05961696withdrawnA Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
NCT05315713terminatedAn Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05205252withdrawnA Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

All Mosunetuzumab trials (54)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT07548450	MPOWER	Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)	P2	not yet recruiting	25	University of Utah	Jun 2026
NCT06284122	MorningLyte	Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5	P3	recruiting	790	The Lymphoma Academic Research Organisation	Jun 2024
NCT05994235		Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma	P2	active not recruiting	23	Weill Medical College of Cornell University	Nov 2023
NCT06492837	FIL_MOZART	Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients	P2	recruiting	56	Fondazione Italiana Linfomi - ETS	Oct 2024
NCT07052695		Mosunetuzumab for CLL MRD Clearance	P1/P2	recruiting	40	Inhye Ahn	Nov 2025
NCT06006117		Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma	P3	recruiting	260	The Lymphoma Academic Research Organisation	Sep 2023
NCT06337318		Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma	P3	recruiting	600	National Cancer Institute (NCI)	Oct 2024
NCT05091424		A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia	P1	recruiting	137	Hoffmann-La Roche	Mar 2022
NCT06948786		Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial	P2	recruiting	22	University of Washington	Nov 2025
NCT06569680		Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma	P2	recruiting	35	Izidore Lossos, MD	Nov 2024
NCT07566364		Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD	P2	not yet recruiting	30	M.D. Anderson Cancer Center	Oct 2026
NCT04246086		A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma	P1/P2	active not recruiting	237	Hoffmann-La Roche	Aug 2020
NCT05633615		Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	P2	recruiting	396	SWOG Cancer Research Network	Jun 2023
NCT06828991	GOLD	A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP	P2	recruiting	40	Danielle Wallace	Sep 2025
NCT06594939		Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma	P2	not yet recruiting	31	Medical College of Wisconsin	Jun 2026
NCT07555470	CUREFL03	Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma	P2	recruiting	80	Institute of Hematology & Blood Diseases Hospital, China	Apr 2026
NCT04712097	Celestimo	A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma	P3	active not recruiting	478	Hoffmann-La Roche	Oct 2021
NCT06634589		A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies	P1/P2	recruiting	80	BeOne Medicines	Nov 2024
NCT05464329		Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma	P1	active not recruiting	24	Washington University School of Medicine	Jan 2023
NCT05169515		A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma	P1	recruiting	121	Hoffmann-La Roche	Oct 2022
NCT05410418		Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma	P2	active not recruiting	34	Washington University School of Medicine	Oct 2022
NCT07191249	SC	A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).	P2	not yet recruiting	30	Tel-Aviv Sourasky Medical Center	Oct 2025
NCT06563505		A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma	P2	recruiting	36	M.D. Anderson Cancer Center	Dec 2024
NCT05260957	NHL	CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).	P2	recruiting	22	Lazaros Lekakis	Dec 2022
NCT04889716		CAR-T Followed by Bispecific Antibodies	P2	recruiting	23	Abramson Cancer Center at Penn Medicine	Nov 2021
NCT06090539		A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas	P1/P2	recruiting	308	Bristol-Myers Squibb	Dec 2023
NCT07598396	SOLUNA	A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis	P2	recruiting	30	Hoffmann-La Roche	May 2026
NCT05849857	MERLIN	Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries	P2	recruiting	80	Oslo University Hospital	Sep 2023
NCT05412290		Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma	P1	active not recruiting	9	Washington University School of Medicine	Dec 2022
NCT06926205	GELLC9RICHTER	CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL	P2	recruiting	34	GELLC (Grupo Español de Leucemia Linfocítica Crónica)	May 2024
NCT06453044		Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma	P2	recruiting	41	City of Hope Medical Center	Sep 2024
NCT04970901	LOTIS-7	A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)	P1	recruiting	200	ADC Therapeutics S.A.	Jun 2022
NCT04792502		Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma	P2	recruiting	52	Brown University	Jul 2022
NCT05615636		A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL	P2	recruiting	36	M.D. Anderson Cancer Center	Apr 2023
NCT05207670	MorningSun	A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies	P2	active not recruiting	320	Genentech, Inc.	Feb 2022
NCT07031700		A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL	P2	not yet recruiting	22	Tianjin Medical University Cancer Institute and Hospital	Jul 2025
NCT06015880		Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	P1	recruiting	30	National Cancer Institute (NCI)	May 2024
NCT06249191		Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma	P1/P2	recruiting	30	OHSU Knight Cancer Institute	Jun 2024
NCT05672251		Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma	P2	recruiting	36	City of Hope Medical Center	Jan 2024
NCT05171647	SUNMO	A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma	P3	active not recruiting	208	Hoffmann-La Roche	Apr 2022
NCT06442475		Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma	P2	recruiting	20	University of Washington	Aug 2024
NCT07278921	MosuOSSHSR	Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).	—	recruiting	25	Andrés José Maria Ferreri	Dec 2025
NCT05389293		A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma	P2	recruiting	152	Memorial Sloan Kettering Cancer Center	May 2022
NCT05886036		Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial	P2	recruiting	70	National Cancer Institute (NCI)	Jan 2024
NCT02500407	NHL	A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	P1/P2	completed	713	Genentech, Inc.	Sep 2015
NCT03677154	BTCT4465A	Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma	P1/P2	completed	188	Hoffmann-La Roche	May 2019
NCT03671018	BTCT4465A	A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma	P1/P2	active not recruiting	422	Hoffmann-La Roche	Sep 2018
NCT05169658		Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma	P2	completed	42	University of Washington	Mar 2022
NCT05155345		A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus	P1	completed	15	Hoffmann-La Roche	Jan 2022
NCT03677141	BTCT4465A	A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma	P1/P2	completed	117	Hoffmann-La Roche	Mar 2019
NCT05961696		A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia	P1	withdrawn	0	M.D. Anderson Cancer Center	Jul 2023
NCT05315713		An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma	P1/P2	terminated	8	Hoffmann-La Roche	May 2022
NCT05205252	ARIA	A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.	P1/P2	withdrawn	0	Epizyme, Inc.	Dec 2021
NCT04313608		A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma	P1	completed	23	Hoffmann-La Roche	Jun 2020

Mosunetuzumab clinical trials: frequently asked questions

How many Mosunetuzumab clinical trials are there?: 54 Mosunetuzumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 31 are actively recruiting participants. 6 are marked completed.
Are Mosunetuzumab clinical trials recruiting in 2026?: Yes — 31 Mosunetuzumab trials are actively recruiting in 2026, with 444 U.S. sites across 45 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Mosunetuzumab being studied for?: Mosunetuzumab is being studied for Follicular Lymphoma, Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma and 91 more. The trials are grouped by indication on this page.
What phase is Mosunetuzumab in?: Mosunetuzumab clinical trials span 5 Phase 3, 28 Phase 2, 9 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Mosunetuzumab clinical trials?: The lead sponsor across the most Mosunetuzumab trials is Hoffmann-La Roche, with 30 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Mosunetuzumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.

Related pages on Hipa.ai:

Mosunetuzumab overview Mosunetuzumab evidence & publications